Traws Pharma Inc (TRAW)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.86M
Last updated: Nov 17, 2026 at 11:03 AM ET
Traws Pharma Inc (TRAW) Competitors
The companies most similar to Traws Pharma are Processa Pharmaceuticals (PCSA), PharmaCyte Biotech (PMCB) and CNS Pharmaceuticals (CNSP). By market cap, Traws Pharma ranks 8th of the 13 companies on this page; GT Biopharma (GTBP) is the largest at $7.67M.
Peer Comparison
TRAW's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Traws Pharma (TRAW) | $3.86M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Processa Pharmaceuticals Inc (PCSA) | $5.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| PharmaCyte Biotech Inc (PMCB) | $3.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Curis Inc (CRIS) | $2.97M | N/A | 1.6x | 0.0% | N/A | -66.0% | 0.00% |
| Azitra Inc (AZTR) | $3.69M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $4.02M | N/A | N/A | 0.0% | -247.2% | 0.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Lantern Pharma Inc (LTRN) | $6.47M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Ernexa Therapeutics Inc. (ERNA) | $2.84M | N/A | N/A | 0.0% | N/A | -94.1% | 0.00% |
| Aprea Therapeutics Inc (APRE) | $5.91M | N/A | N/A | 0.0% | N/A | -98.4% | 0.00% |
| XTL Biopharmaceuticals Ltd ADR (XTLB) | $3.93M | N/A | 4.0x | 0.0% | N/A | 0.0% | 0.00% |
| Purple Biotech (PPBT) | $2.65M | N/A | N/A | 0.0% | -156.2% | 0.0% | 0.00% |
| Peer median | $3.97M | N/A | 2.8x | 0.0% | -201.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Traws Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Processa Pharmaceuticals Inc (PCSA) | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients... | PCSA competitors |
| PharmaCyte Biotech Inc (PMCB) | PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United... | PMCB competitors |
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Curis Inc (CRIS) | Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. | CRIS competitors |
| Azitra Inc (AZTR) | Azitra Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live... | AZTR competitors |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California. | LIMN competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Lantern Pharma Inc (LTRN) | Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics... | LTRN competitors |
| Ernexa Therapeutics Inc. (ERNA) | Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. | ERNA competitors |
| Aprea Therapeutics Inc (APRE) | Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor... | APRE competitors |
| XTL Biopharmaceuticals Ltd ADR (XTLB) | XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment... | |
| Purple Biotech (PPBT) | Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United... | PPBT competitors |
Frequently Asked Questions About TRAW
Who are Traws Pharma's main competitors?
The companies most similar to Traws Pharma include Processa Pharmaceuticals (PCSA), PharmaCyte Biotech (PMCB), CNS Pharmaceuticals (CNSP), Curis (CRIS) and Azitra (AZTR), listed from the closest match.
Who is Traws Pharma's biggest competitor?
GT Biopharma (GTBP) is the largest of the similar companies at $7.67M; Processa Pharmaceuticals (PCSA) is the closest match by business profile, size, sector and industry.
How does TRAW stock compare with its competitors?
TRAW's net margin is 0.0% against a peer median of 0.0%.
Which of Traws Pharma's competitors pays a higher dividend?
Traws Pharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Traws Pharma bigger than its competitors?
No. Traws Pharma is 8th by market cap among the 13 companies on this page; the largest is GT Biopharma (GTBP) at $7.67M.
TRAW pages: Overview, Earnings, Forecast, Financials, Competitors